Cat.No. : CSC-RO0959 Host Cell: CT26
Size: >1x10^6 frozen cells/vial, 1 mL Stability: Stable in culture over a minimum of 10 passages
| Cat. No. | CSC-RO0959 |
| Description | This cell line is engineered to stably overexpress Human ROR1 in CT26 cells. |
| Target Gene | ROR1 |
| Gene Species | Homo sapiens (Human) |
| Host Cell | CT26 |
| Host Cell Species | Mus musculus (Mouse) |
| Stability | Stable in culture over a minimum of 10 passages |
| Application | Drug screening and biological assays |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Size | >1x10^6 frozen cells/vial, 1 mL |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Cancer is one of the leading causes of morbidity and mortality worldwide, with an estimated 19.3 million new cases and nearly 10 million cancer deaths in 2020.ROR1 is a tumor-associated antigen that is overexpressed in a wide range of malignancies. In this study, researchers designed and produced different murine ROR1 fusion proteins to enhance the immunogenicity and protective potency of ROR1. These fusion proteins contained the extracellular region of murine ROR1, an immunogenic fragment of tetanus toxin (TT), and the Fc region of murine IgG2a. The researchers used these fusion proteins to immunize Balb/C mice and evaluated the humoral and cellular immune responses and anti-tumor effects of these fusion proteins in two different syngeneic mouse ROR1+ tumor models. The results showed that all immunized groups of mice produced ROR1-specific antibodies, and in particular, mice immunized with the TT-mROR1-Fc fusion proteins had significantly higher levels of IFN-γ, IL-17, and IL-22 cytokines and a higher frequency of ROR1-specific CTLs. Ultimately, tumor challenge results in immunized mice showed that immunization with the TT-mROR1-Fc fusion protein completely inhibited the growth of ROR1+ tumor cells in both syngeneic tumor models until day 120 post-tumor challenge. These preclinical studies demonstrate for the first time these fusion proteins as potential vaccine candidates for active immunotherapy of ROR1-expressing malignancies.
Figure 1. The researchers used the Balb/C mouse model to study the role of the Human ROR1 stable cell line-CT26 in an in vivo tumor protection assay. Two weeks after immunization, the researchers tumor-challenged the mice with CT26-ROR1+ and 4T1-ROR1+ tumor cells. They then analyzed immunosuppressive cell populations in splenocytes by flow cytometry and measured tumor volume to assess immune response and survival. These approaches revealed the potential of CT26-ROR1+ in immunotherapy. (Hassannia H, et al., 2022)
A: The expression of ROR1 in this cell line provides a system to study its role as an oncofetal antigen and to assess its potential as a biomarker for colorectal cancer. Researchers can evaluate the expression patterns of ROR1 in response to various treatments and correlate them with oncogenic behaviors.
A: This cell line can be employed to assess the specificity and cytotoxic efficacy of ROR1-targeting agents, such as chimeric antigen receptor (CAR) T cells, bispecific antibodies, or antibody-drug conjugates, by monitoring the cell viability and induction of apoptosis upon treatment.
A: By treating the cells with ROR1 ligands or agonists and using inhibitors of known signaling pathways, researchers can delineate which pathways are ROR1-dependent, utilizing techniques like Western blot for pathway markers or reporter assays for pathway activity.
A: Yes, through adhesion and transwell migration assays, the impact of ROR1 on these cellular processes can be quantified. Altering ROR1 expression or function with specific agents and observing changes in these properties can provide insights into how ROR1 may contribute to metastasis.
A: Techniques such as sphere formation assays, flow cytometry for stem cell markers, and drug resistance assays can be used to evaluate how inhibiting ROR1 affects the characteristics and survival of cancer stem cell-like populations within the CT26 cell line.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CT26 cells with stable expression of Human ROR1 maintain reliable levels of the receptor, ensuring consistent experimental outcomes.
Stable ROR1 expression in CT26 cells minimizes genetic drift and ensures the preservation of desired phenotypic characteristics over time.
We can avoid the complexities of transient transfection by using pre-established CT26 cells expressing Human ROR1, streamlining experimental workflows.
The stable ROR1-expressing CT26 cell line serves as a robust platform for high-throughput screening assays and drug discovery efforts targeting ROR1.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
